Antihypertensive agents and renal transplantation

Area of Science:

• Nephrology
• Cardiology
• Transplantation Medicine

Background:

• Kidney transplantation has improved graft survival, highlighting long-term morbidities.
• Hypertension is a significant risk factor for cardiovascular disease and mortality in the general population and kidney transplant recipients.
• Kidney transplant recipients face a high risk of cardiovascular disease, a leading cause of death.

Purpose of the Study:

• To review the impact of arterial blood pressure reduction on patient and graft survival in kidney transplant recipients.
• To discuss the role of hypertension in cardiovascular disease development and left ventricular hypertrophy in this population.
• To guide the selection of antihypertensive agents for optimal renal allograft and cardiovascular outcomes.

Main Methods:

• Review of existing literature and comparative studies on hypertensive and normotensive kidney graft recipients.
• Analysis of factors influencing left ventricular hypertrophy regression post-transplantation.
• Evaluation of antihypertensive drug classes commonly used in kidney transplant patients.

Main Results:

• Hypertension is prevalent and a major risk factor for mortality and cardiovascular events in kidney transplant recipients.
• Cardiovascular disease is the leading cause of death, even with functioning renal allografts.
• Antihypertensive medications, particularly ACE inhibitors/ARBs and beta-blockers, are essential for managing blood pressure and cardiovascular risk.

Conclusions:

• Controlling hypertension is vital for improving long-term patient and graft survival after kidney transplantation.
• Antihypertensive strategies should prioritize cardiovascular protection and regression of left ventricular hypertrophy.
• Careful selection of antihypertensive agents is necessary to maximize benefits for renal allograft function and overall patient well-being.